GlassScriptPhysician profile
Craig E Rumbaugh
NPI 1184019127
$11,006.86
in general payments reported to CMS, 2019-2025
14 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,422 · 2020: $366 · 2021: $1,132 · 2022: $451 · 2023: $585 · 2024: $419 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $3,750.00 | 2019 | |
| Abbott Laboratories | $3,416.58 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Boston Scientific Corporation | $2,500.00 | 2019 | |
| Abbvie INC. | $502.71 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Scilex Pharmaceuticals INC. | $234.93 | 2021-2023 | Ztlido |
| Allergan, INC. | $153.37 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $113.80 | 2021 | |
| Nevro Corp. | $104.31 | 2020 | |
| Lilly USA, LLC | $75.43 | 2020-2023 | Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $53.90 | 2020-2021 | |
| Avanos Medical | $33.76 | 2024 | Generator |
| Tonix Medicines, INC. | $25.24 | 2025 | Tonmya |
| Pfizer INC. | $21.83 | 2025 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Rumbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.